# A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

> **NCT03740555** · PHASE1 · COMPLETED · sponsor: **Guangzhou Henovcom Bioscience Co. Ltd.** · enrollment: 74 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HNC042 single dose
- **DRUG:** Placebo single dose
- **DRUG:** HNC042 multiple ascending doses
- **DRUG:** Placebo multiple ascending doses

## Key facts

- **NCT ID:** NCT03740555
- **Lead sponsor:** Guangzhou Henovcom Bioscience Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2019-07-19
- **Final completion:** 2019-07-19
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740555, "A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03740555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*